Hypera SA (HYPMY)

OTC Markets
Currency in USD
3.28
0.00(0.00%)
Delayed Data
HYPMY Scorecard
Full Analysis
Trading at a low Price / Book multiple
High dividend Yield
Fair Value
Day's Range
3.273.28
52 wk Range
2.647.12
Key Statistics
Edit
Prev. Close
3.28
Open
3.27
Day's Range
3.27-3.28
52 wk Range
2.64-7.12
Volume
842
Average Vol. (3m)
19.95K
1-Year Change
-48.91%
Book Value / Share
3.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HYPMY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period
Show more

Hypera SA Company Profile

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Employees
10301

Compare HYPMY to Peers and Sector

Metrics to compare
HYPMY
Peers
Sector
Relationship
P/E Ratio
7.7x21.4x−0.6x
PEG Ratio
−0.700.060.00
Price / Book
1.0x2.0x2.6x
Price / LTM Sales
1.5x2.3x3.1x
Upside (Analyst Target)
-18.5%52.8%
Fair Value Upside
Unlock14.1%8.4%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.48
Dividend Yield
4.37%
Industry Median 1.80%
Annualized Payout
0.1433
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Oct 24, 2014
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

5.037
EQUEY
+0.74%
5.40
LZRFY
-1.17%
3.1
SLCJY
-0.16%
4.20
VSSPY
0.00%
22.61
CHGCY
-2.50%

FAQ

What Is the Hypera ON (HYPMY) Stock Price Today?

The Hypera ON stock price today is 3.28

What Stock Exchange Does Hypera ON Trade On?

Hypera ON is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Hypera ON?

The stock symbol for Hypera ON is "HYPMY."

Does Hypera ON Pay Dividends? What’s The Current Dividend Yield?

The Hypera ON dividend yield is 4.37%.

What Is the Hypera ON Market Cap?

As of today, Hypera ON market cap is 2.10B.

What is Hypera ON Earnings Per Share?

The Hypera ON EPS is 2.48.

From a Technical Analysis Perspective, Is HYPMY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.